BackCytoDyn Overview

CytoDyn Receivables

Latest receivables for CYDY: $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00
↓ 100.00% YoYΔ $-2.00M vs prior year quarter

Peer trimmed avg / median

Loading

CytoDyn Receivables History

Loading

CytoDyn vs. peers: Receivables Comparison

Loading

CytoDyn Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

CytoDyn (CYDY) FAQ

As of the most recent data (May 2026), CYDY shows a receivables of $0. That compares with $2M in the prior-year period — down 100.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CYDY's receivables is now $0 (was $2M) — a 100.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether CytoDyn is outperforming or lagging.

Tracking CYDY's receivables over time shows whether CytoDyn is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $2M in the prior-year period — down 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has CytoDyn's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.

CytoDyn's receivables is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.